(160) utilized a cyclin-dependent kinase (CDK) 1-FRET biosensor to observe interactions between TP53-mutant cancer cells and CAFs in live tumors, revealing that these interactions delay cancer cell responses to standard chemotherapy. This evidence concerns the gene TP53 and cancer.